Evidence map›Paper›PMID 33809100›Full record

ArticleNanomaterials (Basel, Switzerland)2021

Radiation Crosslinked Smart Peptide Nanoparticles: A New Platform for Tumor Imaging.

Atsushi Kimura, Miho Ueno, Tadashi Arai, Kotaro Oyama, Mitsumasa Taguchi

Abstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Atsushi KimuraTakasaki Advanced Radiation Research Institute (TARRI), National Institutes for Quantum and Radiological Science and Technology (QST), 1233 Watanuki-Machi, Takasaki, Gunma 370-1292, Japan.ORCID 0000-0003-0544-2839
Miho UenoGraduate School of Science and Technology, Gunma University, 1-5-1 Tenjintyo, Kiryu, Gunma 376-8515, Japan.
Tadashi AraiGraduate School of Science and Technology, Gunma University, 1-5-1 Tenjintyo, Kiryu, Gunma 376-8515, Japan.
Kotaro OyamaTakasaki Advanced Radiation Research Institute (TARRI), National Institutes for Quantum and Radiological Science and Technology (QST), 1233 Watanuki-Machi, Takasaki, Gunma 370-1292, Japan.ORCID 0000-0003-4090-025X
Mitsumasa TaguchiTakasaki Advanced Radiation Research Institute (TARRI), National Institutes for Quantum and Radiological Science and Technology (QST), 1233 Watanuki-Machi, Takasaki, Gunma 370-1292, Japan.ORCID 0000-0002-5545-4689

Funding

Japan Society for the Promotion of Science 19K12653, 20K20915
6 · The paper itself

Abstract

Nanoparticles have been employed to develop nanosensors and drug carriers that accumulate in tumors. Thus, it is necessary to control the particle size, surface potential, and biodegradability of these nanoparticles for effective tumor accumulation and safe medical application. In this study, to form a nanoparticle platform suitable for diagnostic and drug delivery system (DDS) applications, peptides composed of aromatic amino acid residues were designed and synthesized based on the radiation crosslinking mechanism of proteins. The peptide nanoparticles, which were produced by γ-ray irradiation, displayed a positive surface potential, maintained biodegradability, and were stable in water and phosphoric buffer solution during actual diagnosis. The surface potential of the peptide nanoparticles could be changed to negative by using a fluorescent labeling reagent, so that the fluorescent-labeled peptide nanoparticles were uptaken by HeLa cells. The radiation-crosslinked nanoparticles can be applied as a platform for tumor-targeting diagnostics and DDS therapy.

Indexed as

nanoparticlepeptideradiation crosslinkingtumor diagnosticsγ-rays

Identifiers

PMID33809100
PMCPMC8000643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.